AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02056418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Description: enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
Study NCT02056418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
Study NCT05292261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational team handball
Description: Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
Study NCT01173965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novasure
Description: Bipolar impedence control system
Study NCT01582230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
Study NCT01582230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
Study NCT02297490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
Study NCT02297490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovit 6-grasses
Description: Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
Study NCT04464291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of Streptococcus pneumoniae strains
Description: There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
Study NCT03521869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression bandage
Description: Compression bandage placed after total knee replacement
Study NCT03521869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: standard of care gauze dressing placed after total knee replacement
Study NCT00327717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
Study NCT00327717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
Study NCT01158261 — intervention group
Intervention type: BIOLOGICAL
Intervention: EVICEL ™ Fibrin Sealant (Human)
Description: Commercial Evicel
Study NCT04004312 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
Study NCT01945346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX167700
Description: Oral capsule
Study NCT01945346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT04884347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alline proMEN
Description: 1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
Study NCT04884347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
Study NCT01417975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Group
Description: Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
Study NCT01417975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Sitting Group
Description: Participants will be required to sit passively on a chair for 10 minutes.
Study NCT03586050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
Study NCT00537186 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iron oligosaccharide
Study NCT01820897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin-Trometamol
Study NCT01820897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole trimethoprim
Study NCT00379899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: Low dose vitamin D with cinacalcet
Study NCT02404610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate Procedural Sedation with a sedative medication.
Description: procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
Study NCT02404610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Procedural Sedation with a sedative medication.
Description: procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
Study NCT02404610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Study NCT02898233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deprexis
Description: Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
Study NCT02898233 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Deprexis
Description: Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
Study NCT02898233 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Deprexis
Description: Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
Study NCT02898233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active low-level light therapy
Description: Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
Study NCT02898233 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low-level light therapy
Description: Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
Study NCT01715701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve blockade
Description: Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
Study NCT01715701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve blockade
Description: Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
Study NCT01715701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia
Description: Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
Study NCT03200210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
Study NCT03200210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills manufactured to mimic Febuxostat tablets
Study NCT02923999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12 Dose Cohort 1
Description: single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
Study NCT02923999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12 Dose Cohort 2
Description: single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
Study NCT02923999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12 Dose Cohort 3
Description: single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
Study NCT01340755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic surgery
Description: Laparoscopy-assisted transanal endoscopic rectosigmoid resection
Study NCT03838939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic education
Description: Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ...
Study NCT03838939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Individual and group therapeutic education sessions will consist of :~* acquisition by patient of self-care skills such as performing subcutaneous injection,~* acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ...
Study NCT02835859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary: saccharin
Description: Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
Study NCT02835859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estimate glucose absorptions
Description: Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
Study NCT01387178 — intervention group
Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol 250µg/50µg (FSC)
Description: Patient records with evidence of COPD and prescription claims for FSC
Study NCT01387178 — intervention group
Intervention type: DRUG
Intervention: tiotropium bromide (TIO)
Description: Patient records with evidence of COPD and prescription claims for TIO
Study NCT01229605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and docetaxel
Description: Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
Study NCT01711853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Dabigatran Etexilate 75mg twice daily
Study NCT03117491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GGNB injections
Description: The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Study NCT03117491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IANB injections
Description: The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Study NCT03117491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GGNB + IANB injections
Description: The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Study NCT01387191 — intervention group
Intervention type: DRUG
Intervention: Epoprostenol
Study NCT03722225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading and high intermittent carbohydrate intake during physical exercise
Description: The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
Study NCT00476164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 doses of 1g 14 days apart
Study NCT02111174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler Therapy
Study NCT00476164 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control arm
Description: Continue of optimised oral immunosuppression
Study NCT02402153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyposafe device
Description: Subcutaneous EEG recorder for EEG measurements
Study NCT02498782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexinidazole
Study NCT02498782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02498782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03622970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VGBT with Nintendo® Wii and LMC games
Description: Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
Study NCT03622970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NDT-based upper limb rehabilitation
Description: NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
Study NCT04225481 — intervention group
Intervention type: OTHER
Intervention: isolation of waste material and culturing with different supplement culture media
Description: isolation of waste material and culturing with different supplement culture media
Study NCT04441944 — intervention group
Intervention type: OTHER
Intervention: Telemedicine
Description: Use of provider-to-provider telemedicine
Study NCT02111174 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Study NCT02909218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Access to ART for All
Description: All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
Study NCT01621776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apidra
Description: Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
Study NCT01621776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
Study NCT01621776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolog
Description: Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
Study NCT01696955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT01696955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01696955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT02259023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid: Sugar sweetened beverage consumption
Description: Sugar sweetened beverage consumption
Study NCT02259023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid: Grain based desserts and candy consumption
Description: Grain based desserts and candy consumption
Study NCT01593605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
Study NCT01593605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol /HMB
Description: resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
Study NCT01593605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo - one tablet taken twice a day by mouth
Study NCT04815980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based mat-based Pilates intervention 3 times a week for 12 weeks prepared by a certified Pilates instructor.
Study NCT02691390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active dTMS
Description: dTMS to ACC
Study NCT02691390 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham dTMS
Description: SHAM - no stimulation
Study NCT02264808 — intervention group
Intervention type: OTHER
Intervention: Developmental Outcomes
Description: A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
Study NCT04990115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: root canal shaping
Description: root canal treatment
Study NCT03923881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Acuity Echo
Description: Optoacoustic imaging with the MSOT Acuity Echo
Study NCT03930095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavior Therapy
Description: The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
Study NCT03930095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive Supportive Therapy
Description: NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
Study NCT00625456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
Study NCT01693913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral exercise and nutrition over
Study NCT01693913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition and exercise education
Study NCT04038112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychological therapy Method of Levels (MOL)
Description: Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
Study NCT00121719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib tablets taken orally, once daily.
Study NCT03588897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutridrink Multi Fibre
Description: Dietary supplementation of 300 kcal for 14 days